CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02293980
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:26.705043+00:00
Published At: 2024-06-17T00:00:00+00:00
Record Updated At: 2024-06-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["ccRCC", "RCC", "Kidney Cancer", "Clear Cell Renal Cell Carcinoma", "Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-06-17"
protocolSection.identificationModule.nctId: "NCT02293980"
protocolSection.identificationModule.officialTitle: "A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2\u03b1 Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.